Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours
AbstractGastrointestinal stromal tumours (GISTs) are soft-tissue sarcomas of the gastrointestinal tract. Surgery is the standard treatment for localised disease, but the risk of relapse and progression to more advanced disease is substantial. Following the discovery of the molecular mechanisms underlying GISTs, targeted therapies for advanced GIST were developed, with the first being the tyrosine kinase inhibitor (TKI) imatinib. Imatinib is recommended in international guidelines as first-line therapy to reduce the risk of GIST relapse in high-risk patients, and for locally advanced, inoperable and metastatic disease. Unfo...
Source: Gastric Cancer - March 13, 2023 Category: Gastroenterology Source Type: research
Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the absence of gross tumor lesions
ConclusionInterruption of imatinib following prolonged maintenance in the absence of gross tumor lesions led to disease progression in the majority of cases. However, re-introduction of imatinib resulted in effective tumor control. Unmaintained remission seems to be possible in some patients with metastatic or recurrent GIST after a prolonged remission with imatinib if there is complete removal of any gross tumor lesions. (Source: Gastric Cancer)
Source: Gastric Cancer - March 8, 2023 Category: Gastroenterology Source Type: research
Possible candidates for splenic hilar nodal dissection among patients with upper advanced gastric cancer without invasion of the greater curvature
ConclusionEven for upper advanced gastric cancer without invasion of the greater curvature, dissection of #10 could be justified for tumors located on the posterior wall with undifferentiated type histology. (Source: Gastric Cancer)
Source: Gastric Cancer - March 7, 2023 Category: Gastroenterology Source Type: research
Nishi memorial award in gastric cancer
(Source: Gastric Cancer)
Source: Gastric Cancer - March 7, 2023 Category: Gastroenterology Source Type: research
Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma —a retrospective, international, multicentric AGEO study
ConclusionNo additional benefit of adding F to T monotherapy as a maintenance treatment could be observed. Reintroduction of initial therapy at first progression may be a feasible approach to preserve later treatment lines. (Source: Gastric Cancer)
Source: Gastric Cancer - March 7, 2023 Category: Gastroenterology Source Type: research
Risk factors of “loss of independence” in elderly patients who received gastrectomy for gastric cancer
ConclusionsLOI after gastrectomy was independently associated with high FI, older age ( ≥ 75 years), and major (CD ≥ 3) complications. A simple risk score assigning points for these factors was an accurate predictor of postoperative LOI. We propose that frailty screening should be applied for all elderly GC patients before surgery. (Source: Gastric Cancer)
Source: Gastric Cancer - March 7, 2023 Category: Gastroenterology Source Type: research
Possible candidates for splenic hilar nodal dissection among patients with upper advanced gastric cancer without invasion of the greater curvature
ConclusionEven for upper advanced gastric cancer without invasion of the greater curvature, dissection of #10 could be justified for tumors located on the posterior wall with undifferentiated type histology. (Source: Gastric Cancer)
Source: Gastric Cancer - March 7, 2023 Category: Gastroenterology Source Type: research
Nishi memorial award in gastric cancer
(Source: Gastric Cancer)
Source: Gastric Cancer - March 7, 2023 Category: Gastroenterology Source Type: research
Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma —a retrospective, international, multicentric AGEO study
ConclusionNo additional benefit of adding F to T monotherapy as a maintenance treatment could be observed. Reintroduction of initial therapy at first progression may be a feasible approach to preserve later treatment lines. (Source: Gastric Cancer)
Source: Gastric Cancer - March 7, 2023 Category: Gastroenterology Source Type: research
Risk factors of “loss of independence” in elderly patients who received gastrectomy for gastric cancer
ConclusionsLOI after gastrectomy was independently associated with high FI, older age ( ≥ 75 years), and major (CD ≥ 3) complications. A simple risk score assigning points for these factors was an accurate predictor of postoperative LOI. We propose that frailty screening should be applied for all elderly GC patients before surgery. (Source: Gastric Cancer)
Source: Gastric Cancer - March 7, 2023 Category: Gastroenterology Source Type: research
LOC101929709 promotes gastric cancer progression by aiding LIN28B to stabilize c-MYC mRNA
ConclusionsThe c-MYC/LOC101929709/LIN28B axis promotes aerobic glycolysis and tumour progression. Thus, LOC101929709 can be a novel potential target for gastric cancer treatment. (Source: Gastric Cancer)
Source: Gastric Cancer - March 1, 2023 Category: Gastroenterology Source Type: research
